Sareum Holdings PLC
("Sareum" or the "Company")
Exercise of Share Options and Director Dealings
Cambridge, UK, 2 November 2023 - Sareum Holdings plc (AIM: SAR), a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, announces that on 30 October 2023, Dr Tim Mitchell, Chief Executive Officer, and Dr John Reader, Chief Scientific Officer, each exercised options over 95,040 ordinary shares of 1.25 pence each ("New Ordinary Shares") in the Company (the "Options"), at an exercise price of 30 pence per New Ordinary Share, for an aggregate consideration of £57,024.
The Options were granted on 18 December 2013, under the Sareum Holdings plc Enterprise Management Incentives Option Agreement, and were due to lapse on 17 December 2023.
On exercise, Dr Mitchell and Dr Reader noted their intention to sell a proportion of such New Ordinary Shares in the market on receipt, partly in order to compensate for the cost and tax liabilities arising from the exercise. A further announcement will be released in due course disclosing such sales.
Following Admission (as defined below), Dr Mitchell's and Dr Reader's resultant interests in the Company will be as follows:
| Director/ | Date of transaction | Number of shares purchased via Option exercise | Purchase price | Total shares held | Percentage of issued share capital |
| Tim Mitchell (1) | 30 October 2023 | 95,040 | 30p | 1,104,561
| 1.57% |
| John Reader (2) | 30 October 2023 | 95,040 | 30p | 1,127,537
| 1.60% |
(1) - Included within Tim Mitchell's total holding are 200,000 Ordinary Shares held by his spouse.
(2) - Included withing John Reader's total holding are 66,666 Ordinary Shares held by his spouse. Please note this record corrects the typographical error in respect of John Reader's shareholding announced on 3 November 2021.
Admission
Application has been made to the London Stock Exchange for the 190,080 New Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 3 November 2023.
Following Admission, the total number of Ordinary Shares in issue will be 70,261,878 and the total number of voting rights will therefore be 70,261,878. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
For further information, please contact:
| Sareum Holdings plc Tim Mitchell, CEO Lauren Williams, Head of Investor Relations
|
01223 497700 ir@sareum.co.uk |
| Strand Hanson Limited (Nominated Adviser) James Dance / James Bellman
|
020 7409 3494 |
| Peel Hunt LLP (Joint Corporate Broker) James Steel / Patrick Birkholm
|
020 7418 8900 |
| Hybridan LLP (Joint Corporate Broker) Claire Noyce
ICR Consilium (Financial PR) Jessica Hodgson / Davide Salvi / Stella Lempidaki
|
020 3764 2341
020 3709 5700 |
PDMR Notification Forms
The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | Tim Mitchell | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chief Executive Officer | ||||
| b) | Initial notification/amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | SAREUM HOLDINGS PLC | ||||
| b) | LEI | 213800PKERN2DY8FFM72 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 1.25p each in the share capital of Sareum Holdings plc | ||||
| Identification code | ISIN for Ordinary Shares: GB00B02RFS12 | |||||
| b) | Nature of the Transaction | Exercise of Options to acquire ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
| ||||
| e) | Date of the transaction | 30 October 2023 | ||||
| f) | Place of the transaction | London Stock Exchange (AIM) | ||||
| 1. | Details of the person discharging managerial responsibilities / person closely associated | |||||
| a) | Name | John Reader | ||||
| 2. | Reason for the Notification | |||||
| a) | Position/status | Chief Scientific Officer | ||||
| b) | Initial notification/amendment | Initial notification | ||||
| 3. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
| a) | Name | SAREUM HOLDINGS PLC | ||||
| b) | LEI | 213800PKERN2DY8FFM72 | ||||
| 4. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted | |||||
| a) | Description of the Financial instrument, type of instrument | Ordinary shares of 0.025p each in the share capital of Sareum Holdings plc | ||||
| Identification code | ISIN for Ordinary Shares: GB00B02RFS12 | |||||
| b) | Nature of the Transaction | Exercise of Options to acquire ordinary shares | ||||
| c) | Price(s) and volume(s) |
| ||||
| d) | Aggregated information - Aggregated volume - Price |
| ||||
| e) | Date of the transaction | 30 October 2023 | ||||
| f) | Place of the transaction | London Stock Exchange (AIM) | ||||
About Sareum
Sareum Holdings (AIM:SAR) is a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.
The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases and has entered Phase 1a/b clinical development with an initial focus on psoriasis.
Sareum has an economic interest in SRA737, a clinical-stage Chk1 inhibitor which it originally developed in collaboration with several Cancer Research UK-related organisations. SRA737 has shown promising safety and efficacy in two Phase 1/2 clinical trials.
Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy.
Sareum Holdings plc is based in Cambridge, UK, and is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com
- Ends -
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.